Costamare Inc. Announces Implementation of Dividend

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Costamare Inc. Announces Implementation of Dividend Reinvestment Plan

MONACO--(Marketwired - Jul 6, 2016) -  Costamare Inc. (the "Company") ( NYSE : CMRE ) announced today that its Board of Directors has voted to implement a dividend reinvestment plan (the "plan"). The plan offers holders of Company common stock the opportunity to purchase additional shares by having their cash dividends automatically reinvested in Company common stock. Participation in the plan is optional, and shareholders who decide not to participate in the plan will continue to receive cash dividends, as declared and paid in the usual manner. All dividends with respect to Company common stock are payable only when and as declared by the Company's board of directors.

The following is a summary of the key attributes of the plan. The terms and conditions of the plan are set forth under the heading "Description of Plan" in the prospectus available as part of the registration statement filed by the Company with the Securities and Exchange Commission (the "SEC") on the SEC's website, EDGAR ( http://www.sec.gov ). Shareholders should read the plan prospectus carefully before electing to participate in the plan or invest in Company common stock. 

The plan will be administrated by American Stock Transfer & Trust, LLC (the "Administrator"), the Company's transfer agent. At the Company's discretion, the Administrator will make such purchases directly from the Company, on the open market, through privately negotiated transactions or by a combination of the foregoing. Purchases directly from the Company may be eligible for a discount of up to 5% from the otherwise applicable purchase price, but any such discount is to be determined by the Company's board of directors, in its sole discretion, and may be changed or discontinued at any time without notice to plan participants. The Company has instructed the Administrator that, until further notice, all purchases under the plan shall be made directly from the Company at a discount of 3% to the Market Price (as defined in the plan).

Plan enrollment materials and information will be distributed to the Company's shareholders of record. Dividend reinvestments under the plan are expected to begin with the dividend declared by the Company's board of directors in respect of the quarter ended June 30, 2016. Record owners of Company common stock may participate in the plan by submitting a properly completed plan enrollment form to the Administrator. Beneficial owners of Company common stock may participate in the plan either by becoming a record owner in respect of the shares they would like to enroll in the plan and then submitting a properly completed enrollment form to the Administrator or by arranging for the broker, bank or other nominee that is the record owner in respect of such shares to participate in the plan on their behalf. If a plan enrollment form is received by the Administrator on or prior to the record date established for a particular dividend, reinvestment will commence with that dividend. Enrollment forms of shareholders who wish to participate in the plan for the dividend declared in respect of the quarter ended June 30, 2016 must be received by the Administrator no later than August 3, 2016. For more information on how to enroll or any other inquiries, contact the Administrator by phone at (800) 279-4353 or via the Internet at www.amstock.com .

This release does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The offering is being made only by means of a prospectus. The Company has filed a registration statement (including a prospectus) relating to the plan with the SEC. A copy of the registration statement (including the prospectus) is available electronically from EDGAR ( http://www.sec.gov ) and may also be obtained from the Administrator by phone at (800) 279-4353 or via the Internet at www.amstock.com

About Costamare Inc. Costamare Inc. is one of the world's leading owners and providers of containerships for charter. The Company has 42 years of history in the international shipping industry and a fleet of 72 containerships, with a total capacity in excess of 467,000 TEU, including 10 newbuild containerships on order. The Company's common stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock trade on the New York Stock Exchange under the symbols "CMRE", "CMRE PR B", "CMRE PR C" and "CMRE PR D", respectively.

Forward-Looking Statements This press release contains "forward-looking statements". In some cases, you can identify these statements by forward-looking words such as "believe", "intend", "anticipate", "estimate", "project", "forecast", "plan", "potential", "may", "should", "could" and "expect" and similar expressions. These statements are not historical facts but instead represent only the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that actual results may differ, possibly materially, from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in the Company's Annual Report on Form 20-F (File No. 001-34934) under the caption "Risk Factors".

Company Contacts: Gregory Zikos Chief Financial Officer Konstantinos Tsakalidis Business Development, Investor Relations Costamare Inc., Monaco Tel: (+377) 93 25 09 40 Email: ir@costamare.com Plan Administrator: American Stock Transfer & Trust Company, LLC 6201 Fifteenth Avenue Brooklyn, New York 11219 Tel: (800) 279-4353

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 241

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 431

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 325

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 210

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Brixton Metals Delivers Promising Drill Results in Thorn Project

Updated Category News Views 167

Brixton Metals' Latest Drill Results Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) recently unveiled its second batch of drill results from the 2025 exploration season. The company operates the Thorn Project, an underexplored district known for its potential in copper-gold porphyry deposits. Highlighting Impressive Assay Results The recent drilling at the...

Continue Reading
US Labor Market Stagnation: A Closer Look at 2025 Trends

Updated Category News Views 275

November Layoffs and Hiring Trends In November, layoffs by U.S. employers reduced significantly, signaling a shift in the job market dynamics. Yet, companies are still hesitant to recruit new employees, indicating a labor market that remains restrained due to various pressures. Businesses are facing challenges such as soft demand, tariff implications, and soaring...

Continue Reading
Dollar Steady Amid Global Market Uncertainty and Yuan Weakness

Updated Category News Views 127

Asian Currency Markets React to U.S. Dollar Strength In the bustling arena of Asian currencies, the atmosphere is charged with anticipation as investors monitor the situation in China regarding potential economic stimulus measures. Meanwhile, the U.S. dollar is exhibiting remarkable strength, currently hovering near a two-and-a-half month high. This rise comes in light of...

Continue Reading
Understanding Recent Insider Trades at Omega Healthcare Invts

Updated Category News Views 75

Examining Insider Trades at Omega Healthcare Invts Recently, a notable insider trade involving Omega Healthcare Invts has drawn attention. Chief Operating Officer Daniel Booth executed a significant transaction, selling 56,725 shares as disclosed through an SEC filing. This particular sale took place on a recent date and revealed a total transaction value of $2,283,181....

Continue Reading
Exploring Future Growth in Healthcare Digital Payments Market

Updated Category News Views 150

Introduction to Digital Payments in Healthcare The transformation in the realm of healthcare is not just about treatments and services; it extends deeply into how payments are managed. The Digital Payment in Healthcare Market is evolving, with an anticipated growth in value reaching USD 61,521.8 Million by the year 2033. This incredible increase is projected to occur at a...

Continue Reading